China Healthcare Weekly (Jan.12) - Haier Biomedical and RAAS Terminated Their Merger
​China's medical insurance fund will increase reimbursement for innovative drug. Commercial insurance need to increase percentage in hospital...
605 Views
China Healthcare Weekly (Dec.29) - Haier Biomedical Plans to Merge with and Absorb Shanghai RAAS
​Haier to merge with RAAS, enhancing dominance in blood products industry and improving financial performance.The deal is clearly more beneficial...
695 Views
(Desperate) Takeover Bid in the Making
Grifols' founding families and Brookfield ask the Board for the necessary information to evaluate an offer for 100% of Grifols SA (GRF SM). The...
313 Views
Another Debt Downgrade
​Moody's downgrades Grifols' rating due to high leverage and opaque governance. For risk-tolerant investors, the current low share price could...
389 Views
Tiantan (600161CH) To Acquire Weiguang (002880CH)- New King Rises in China's Blood Products Industry
The change of Weiguang's actual controller will bring about a series of restructuring.As SOE reform enters new stage, investors will have good...
421 Views